妊娠期缺铁筛查基于铁蛋白阈值的成本效果分析
该研究从改良美国社会视角首次对孕妇铁蛋白缺铁筛查进行成本效果分析,比较30 μg/L、15 μg/L和不筛查三种策略。结果显示30 μg/L筛查为优选策略,增量成本效果比为每QALY 34 000美元(95%可信区间32 000-36 200美元/QALY)。
要点
- 妊娠期铁蛋白30 μg/L筛查优于15 μg/L及不筛查策略
- 30 μg/L筛查增量成本效果比为34 000美元/QALY
- 建议美国所有孕妇考虑孕中晚期规律缺铁筛查
核心结论
- 妊娠期基于铁蛋白的缺铁筛查中,30 μg/L阈值是成本效果优选策略。
研究设计与样本
- 研究为美国孕妇铁蛋白缺铁筛查的成本效果分析,比较30 μg/L、15 μg/L和不筛查三种策略,采用改良美国社会视角。
主要发现
- 30 μg/L筛查相比不筛查的增量成本效果比为34 000美元/QALY(95%可信区间32 000-36 200美元/QALY)。
- 在所有考察的支付意愿阈值下,30 μg/L均为优选策略,且在10 000次蒙特卡洛迭代中100%被 favoring。
关键数值与推荐
- 世界卫生组织对孕早期缺铁采用15 μg/L的诊断性铁蛋白阈值,未提供孕中晚期指导。
- 30 μg/L筛查相比不筛查的增量成本效果比为34 000美元/QALY(95%可信区间32 000-36 200美元/QALY)。
临床怎么用
- 可考虑对美国所有孕妇在孕中晚期采用生理学铁蛋白范围进行规律缺铁筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Maternal iron deficiency (ID) affects nearly 85% of all pregnancies worldwide by the third trimester and is strongly linked with maternal morbidity, poor birth outcomes, and cognitive and behavioral developmental deficits in children. Despite its burden on maternofetal health, no guidelines exist for routine screening of ID in pregnant individuals in the United States. The World Health Organization uses a diagnostic (ie, nonscreening) ferritin threshold of 15 μg/L for ID in the first trimester of pregnancy, with no guidance for the second and third trimesters. Routine screening for ID in pregnancy could identify a large proportion of mothers who remain undiagnosed and untreated under the current clinical status quo. Accordingly, we conducted, to our knowledge, the first cost-effectiveness analysis of ferritin-based ID screening in pregnant women in the United States, comparing thresholds of (1) 30 μg/L vs (2) 15 μg/L vs (3) no screening from a modified US societal perspective accounting for wages lost to infusion time, infusion administration costs, and the cost of annual hematology follow-up. We found that screening at 30 μg/L was the preferred strategy across extensive base-case, threshold, and sensitivity analyses and across all examined willingness-to-pay thresholds, with an incremental cost-effectiveness ratio of $34 000/quality-adjusted life year (QALY; 95% credible interval, $32 000-$36 200/QALY) compared with no screening. No parameter variation changed this outcome, and screening at 30 μg/L was favored in 100% of 10 000 Monte Carlo iterations. Population-level regular second- and third-trimester screening for ID using physiologically informed ferritin ranges should be considered for all pregnant women in the United States.
引用
- Wang D, Sra M, Ng DQ, et al. Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds. Blood Adv. 2026. PMID: 42206692. doi:10.1182/bloodadvances.2026020143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。